Wy'East

Wy'East Therapeutics is a biotechnology company focused on developing novel small molecule therapeutics that target G protein-coupled receptors (GPCRs) through allosteric modulation. By focusing on 'biased' signaling, the company aims to create drugs that selectively trigger beneficial pathways while avoiding those that cause adverse effects. Their primary research is centered on the M2 muscarinic receptor, with applications in treating chronic respiratory conditions like asthma and COPD. The company originated as a spin-off from Oregon Health & Science University (OHSU), leveraging the expertise of its founding scientists in airway pharmacology. Wy'East Therapeutics operates within the Portland, Oregon biotech ecosystem, utilizing its platform to address unmet needs in inflammatory disease management.